Industry Trends

The United States is the only profit-motivated healthcare system in the world, and perhaps it is no coincidence that this country also has the most expensive healthcare of any nation.
Self-funded plan sponsors of commercial insurance health plans include employers, municipality governments, and unions. In many areas, a coalition of plan sponsors work together in partnership to purchase and/or manage healthcare benefits, such as prescription drugs, as a benefit carve-out from their medical benefits.
Many of the 2016 healthcare trends began between 2012 and 2014 and finally emerged more clearly in 2015 for commercially insured populations.
The shift in the drug development pipeline to specialty drug domination is transforming the pharmacy benefits industry.
The growth of spending on healthcare in the United States dropped to historical lows in the past few years but rose up in 2014 and is expected to continue increasing.
Cancer is already the largest clinical area of drug spending in the United States, and a cluster of innovative medicines utilizing new mechanisms of action for patients with a wide variety of tumor types promise to further increase cancer-related spending.

Chronic disease is responsible for 7 of 10 deaths in the United States and 75% of the nation’s $2.2- trillion healthcare bill.1,2 According to the American Diabetes Association, nearly 26 million Americans have diabetes, and more than 200,000 die of this chronic disease annually. Patients with diabetes are at increased risk for diabetes-related complications, includ­ing heart disease, stroke, kidney failure, blindness, and lower-limb amputations.3

Rosacea is a chronic skin disease that often requires continuous treatment, but data about healthcare utilization and the costs associated with its management have been lacking, especially for relatively newer therapies. James D. Kendall, PharmD, and Norman J. Preston, PhD, of Galderma Laboratories, LP, recently addressed this information gap in a poster presentation at the 2013 Academy of Managed Care Pharmacy Nexus meeting.1/P

Pulmonary arterial hypertension (PAH) is a chronic, debilitating, and life-threatening disease of the pulmonary vasculature characterized by remodeling of the small pulmonary arteries. The estimated prevalence of PAH in the United States is 12.4 cases per 1 million people, with an annual incidence of 2.3 cases per 1 million.1 Although these figures suggest that the disease is relatively rare, the societal impact is significant; morbidity and mortality rates for patients with PAH are high, and high-cost hospital stays are common.

At the American Medical Group Association 2013 Institute for Quality Leadership annual conference, a session focused on transforming the US healthcare system was presented by Jim Carroll, author of Ready, Set, Done: How to Innovate When Faster is the New Fast, who discussed the ways in which the unprecedented technological changes in medicine can transform the system in a positive way, in a very short time.
Page 2 of 8
Results 11 - 20 of 73
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME